Jason Romancik, MD, discusses efforts to maximize the efficacy of CAR T-cell therapy in non-Hodgkin lymphoma.
Jason Romancik, MD, assistant professor, Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, discusses efforts to maximize the efficacy of CAR T-cell therapy in non-Hodgkin lymphoma (NHL).
Advancements in CAR T-cell therapy have allowed patients with NHL to potentially experience long-term remission, Romancik says. However, a minority of patients achieve this outcome, creating an unmet need to improve the efficacy of this therapeutic option, Romancik says.
Several studies investigated the use of CAR T-cell therapies in earlier treatment lines and showed increased efficacy vs current standard-of-care options, Romancik notes. Moreover, there is interest in utilizing this therapy for the first-line treatment of high-risk patient populations, Romancik adds.
CAR T-cell therapy can lead to delayed treatment administration, which decreases patient outcomes, Romancik continues. However, the use of allogeneic CAR T-cell products could help minimize these factors, Romancik concludes.